Novartis Advertising Cited By FDA For Fifth Time In Less Than A Year
This article was originally published in The Pink Sheet Daily
Executive Summary
CBER's Advertising and Promotional Labeling Branch says that Novartis improperly expanded the age range for its Fluvirin influenza vaccine.
You may also be interested in...
Drug Ads Should Take A Long View, DDMAC Says In Citing Time-To-Onset Claims
FDA sends notice of violation letters to Dow Pharmaceutical Sciences (Valeant) and Novartis for stretching a point in promotional materials for Acanya Gel and Focalin XR, respectively.
Drug Ads Should Take A Long View, DDMAC Says In Citing Time-To-Onset Claims
FDA sends notice of violation letters to Dow Pharmaceutical Sciences (Valeant) and Novartis for stretching a point in promotional materials for Acanya Gel and Focalin XR, respectively.
Exforge Money-back Guarantee Leaves DDMAC Complaining
Novartis sales aid touting money-back guarantee on its blood pressure product implies the drug is more effective than competitors with no head-to-head evidence, FDA maintains.